These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 25981661)

  • 1. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
    Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
    Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
    Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
    Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.
    Yamao K; Takenaka M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Kamata K; Minaga K; Hagiwara S; Sakurai T; Nishida N; Chiba Y; Watanabe T; Kudo M
    Intern Med; 2019 Jul; 58(14):1993-2002. PubMed ID: 30996164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary Prophylactic Administration of Pegfilgrastim in FOLFIRINOX Therapy for Locally Advanced Pancreatic Carcinoma].
    Ninomiya R; Nakazawa A; Miyata Y; Mitsui T; Komagome M; Maki A; Ozawa F; Beck Y
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1678-1680. PubMed ID: 28133096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
    Cardot-Ruffino V; Bollenrucher N; Delius L; Wang SJ; Brais LK; Remland J; Keheler CE; Sullivan KM; Abrams TA; Biller LH; Enzinger PC; McCleary NJ; Patel AK; Rubinson DA; Schlechter B; Slater S; Yurgelun MB; Cleary JM; Perez K; Dougan M; Ng K; Wolpin BM; Singh H; Dougan SK
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
    Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
    Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis.
    Carvalho de Brito AB; Riechelmann RP; Fonseca de Jesus VH
    Cancer Control; 2023; 30():10732748221149543. PubMed ID: 36592369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
    Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
    Soda H; Oka M; Fukuda M; Kinoshita A; Sakamoto A; Araki J; Fujino S; Itoh N; Watanabe K; Kanda T; Nakano M; Hara K
    Cancer Chemother Pharmacol; 1996; 38(1):9-12. PubMed ID: 8603458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
    Ho P; Sherman P; Grigg A
    Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patients.
    Chan A; McGregor S; Liang W
    Breast; 2014 Oct; 23(5):676-82. PubMed ID: 25108452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.